Peptide Research Profile

KPV

Lys-Pro-Val — C-Terminal Tripeptide of α-Melanocyte Stimulating Hormone (α-MSH)

Evidence Grade: Preclinical Only · All Data In Vitro / Rodent

A tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte stimulating hormone (α-MSH), a 13-amino-acid neuropeptide with potent anti-inflammatory properties. KPV retains the anti-inflammatory signaling activity of full-length α-MSH without the melanocortin receptor-mediated effects on pigmentation or appetite. Its primary mechanism involves NF-κB pathway inhibition and MC1R-independent anti-inflammatory signaling. Despite strong in vitro and rodent colitis data, KPV has zero published human clinical trials. The oral bioavailability of a tripeptide is expected to be negligible.

Medical Disclaimer: This profile is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. KPV has zero human clinical data. ALL evidence is from cell culture and rodent models. Oral bioavailability is expected to be negligible for a tripeptide. Always consult a qualified healthcare professional before using any peptide compound. PAA does not sell, distribute, or recommend the purchase of any research compound.

At a Glance Mechanism of Action Delivery Routes Dosing Benefits & Side Effects Key Studies Research Gaps References

Quick Reference

At a glance

Classification

Tripeptide

3 amino acids (Lys-Pro-Val) — C-terminal fragment of α-MSH (residues 11-13)

Primary Research

Anti-Inflammatory

NF-κB inhibition, colitis models, skin inflammation models

Evidence Level

Preclinical

In vitro + rodent models only • Zero human clinical trials

Key Pathway

NF-κB Inhibition

Blocks IκBα phosphorylation and p65 nuclear translocation • Possible MC1R-independent action

Pharmacology

Mechanism of action

KPV’s anti-inflammatory properties derive from the C-terminal signaling motif of α-MSH, which is responsible for much of the parent molecule’s immunomodulatory activity. Full-length α-MSH acts primarily through melanocortin-1 receptor (MC1R) to suppress inflammation, but KPV appears to retain anti-inflammatory signaling through a mechanism that may be partly MC1R-independent — likely involving direct intracellular NF-κB pathway inhibition after cellular uptake via peptide transporters. The dissociation of anti-inflammatory activity from melanogenic activity is KPV’s key distinction from full-length α-MSH.

Cellular Uptake via Peptide Transporters

KPV is a very small tripeptide (342 Da) that can be taken up by cells via PepT1 (SLC15A1) and PepT2 (SLC15A2), the proton-coupled oligopeptide transporters expressed in intestinal epithelial cells, immune cells, and keratinocytes. This transporter-mediated uptake allows KPV to enter cells and act intracellularly, bypassing the need for cell-surface receptor binding. PepT1 is highly expressed on colonocytes, which may explain KPV’s efficacy in colitis models despite oral delivery challenges.

PepT1 biology: PepT1 (SLC15A1) is the major intestinal di/tripeptide transporter, responsible for absorbing dietary peptide fragments and peptidomimetic drugs (e.g., aminopenicillins, ACE inhibitors). It transports di- and tripeptides using a proton gradient. KPV’s Lys-Pro-Val sequence is a good PepT1 substrate based on structure-activity relationships. In the inflamed colon, PepT1 expression is paradoxically upregulated on immune cells (macrophages, neutrophils) that don’t normally express it, potentially allowing KPV to target immune cells specifically in the inflammatory milieu. This has been proposed as a mechanism for KPV’s efficacy in colitis models.

NF-κB Pathway Inhibition

The core anti-inflammatory mechanism: KPV inhibits the NF-κB signaling cascade by blocking IκB kinase (IKK) activity. This prevents phosphorylation and degradation of IκBα (the NF-κB inhibitor protein), keeping the p50/p65 NF-κB dimer sequestered in the cytoplasm. Without nuclear translocation, NF-κB cannot activate transcription of pro-inflammatory genes (TNF-α, IL-1β, IL-6, IL-8, COX-2, iNOS). In LPS-stimulated macrophages, KPV reduces TNF-α production by 50–70% at micromolar concentrations.

Signaling detail: The canonical NF-κB pathway: TLR4/TNF-R activation → TRAF6/RIP1 → TAK1 activation → IKKβ phosphorylation → IκBα phosphorylation at Ser32/Ser36 → ubiquitination and proteasomal degradation of IκBα → p65/p50 nuclear translocation → inflammatory gene transcription. KPV appears to inhibit at the IKK level, though the exact binding interaction is not characterized. Importantly, NF-κB is not only pro-inflammatory — it is also essential for immune defense, cell survival, and tissue homeostasis. Chronic NF-κB suppression is immunosuppressive, which is both the therapeutic goal (in inflammation) and the safety concern (infection risk).

MC1R-Dependent & Independent Pathways

Full-length α-MSH exerts anti-inflammatory effects primarily through melanocortin-1 receptor (MC1R) activation, which triggers Gαs/cAMP signaling that suppresses NF-κB. The question of whether KPV acts through MC1R or independently is debated. Some evidence shows KPV retains anti-inflammatory activity in MC1R-null cells, suggesting an MC1R-independent mechanism (possibly direct intracellular action after PepT1 uptake). Other studies show reduced KPV efficacy with MC1R antagonists.

The MC1R debate: Getting et al. (2006) showed KPV reduced inflammatory cytokines in MC1R-expressing and MC1R-deficient macrophages, suggesting at least partial MC1R-independent activity. Dalmasso et al. (2008) showed KPV’s colonic anti-inflammatory effect required PepT1-mediated uptake, supporting an intracellular mechanism. However, Brzoska et al. (2008) demonstrated that MC1R antagonism partially blocked α-MSH fragment activity. The current consensus is that KPV likely acts through both MC1R-dependent (extracellular, cAMP-mediated) and MC1R-independent (intracellular, direct NF-κB inhibition after PepT1 uptake) pathways, with relative contributions depending on cell type and inflammatory context.

Anti-Inflammatory Effects in Colitis Models

The strongest preclinical data for KPV is in rodent colitis models. In DSS (dextran sodium sulfate) and TNBS colitis models, KPV administered intraperitoneally or in nanoparticle-encapsulated oral formulations reduced colonic inflammation markers (MPO, inflammatory cytokines), decreased histological damage scores, and improved clinical parameters (weight loss, stool consistency, rectal bleeding). These results are consistent and have been replicated across several independent laboratories.

Colitis data specifics: Dalmasso et al. (2008) showed that oral KPV-loaded alginate-chitosan nanoparticles (designed to release in the colon) reduced DSS colitis severity by ~60% as measured by disease activity index. Colonic TNF-α was reduced by 70%, and MPO activity (neutrophil infiltration marker) was reduced by 55%. The nanoparticle formulation was critical — free KPV given orally was ineffective (degraded before reaching the colon), but encapsulated KPV achieved therapeutic concentrations at the colonic mucosa. This suggests that systemic KPV delivery is not necessary for colonic effects — local delivery may be sufficient, which is therapeutically attractive.

Skin Anti-Inflammatory Effects

KPV has shown anti-inflammatory activity in skin inflammation models, consistent with α-MSH’s known role in cutaneous immune regulation. In keratinocyte and dermal fibroblast cultures, KPV reduces UV-induced and TNF-α-induced NF-κB activation and cytokine production. These findings have driven community interest in KPV for skin conditions, though no human dermatological study has been conducted.

Skin biology context: The skin has its own melanocortin system. Keratinocytes, melanocytes, fibroblasts, and dermal immune cells all express MC1R and produce α-MSH locally. UV radiation induces α-MSH production as part of the skin’s stress response, and α-MSH-MC1R signaling is anti-inflammatory and photoprotective. KPV could theoretically supplement this endogenous system in inflammatory skin conditions (atopic dermatitis, psoriasis, UV damage). However, topical delivery of a tripeptide faces formulation challenges, and no human topical KPV study exists.

Administration

Delivery routes

Subcutaneous Injection

Community Use

The most common community administration route. Reconstituted from lyophilized powder. For a tripeptide, SC bioavailability should be reasonable given the small molecular size. However, systemic half-life is expected to be very short (minutes) due to rapid peptidase degradation of such a small peptide. No human PK data exists for SC KPV.

Oral (Free Peptide)

Likely Ineffective — Degraded Before Absorption

Free oral KPV is almost certainly ineffective for systemic or colonic delivery. A tripeptide is rapidly degraded by gastric acid, pepsin, and pancreatic peptidases. Even if some survives to the small intestine, PepT1 absorption would be followed by immediate hepatic first-pass degradation. The Dalmasso colitis study showed free oral KPV was ineffective — only nanoparticle-encapsulated oral KPV worked.

Oral (Nanoparticle-Encapsulated)

Research Only — Rodent Studies

Alginate-chitosan nanoparticle encapsulation protects KPV from gastric degradation and provides colonic release. This formulation was effective in rodent colitis models. However, this nanoparticle formulation is a research tool, not a commercially available product. Community “oral KPV” capsules do NOT contain nanoparticle encapsulation and are expected to be ineffective.

Topical

Theoretical — No Data

Topical application for skin inflammation is theoretically interesting given KPV’s dermal anti-inflammatory data in cell culture. However, a tripeptide’s ability to penetrate the stratum corneum is limited. Specialized delivery vehicles (liposomes, penetration enhancers) would likely be needed. No topical KPV product has been tested in humans.

Protocols

Dosing reference

No established human dosing exists for KPV. All efficacy data is from cell culture and rodent studies. Community dosing is entirely arbitrary.

Context	Dose	Frequency	Source
In vitro anti-inflammatory	1–100 μM Cell culture — not translatable to injection dose	Single treatment	Multiple in vitro studies
Rodent colitis (IP)	120 mcg IP Mouse dose, ~6 mg/kg	Daily for 7 days	Dalmasso et al., 2008
Rodent colitis (nanoparticle oral)	430 mcg/day oral Alginate-chitosan nanoparticle formulation	Daily for 7 days	Dalmasso et al., 2008
Community SC protocol	200–500 mcg SC No human PK or efficacy data	Daily for 2–4 weeks	Anecdotal / community — zero clinical evidence

Important: There is NO established human dose for KPV by any route. The community SC doses are arbitrary. The oral community doses (taken as capsules without nanoparticle encapsulation) are almost certainly ineffective because the tripeptide is degraded before reaching any target tissue. If you are taking oral KPV capsules, you are very likely taking an expensive placebo.

Outcomes

Benefits & side effects

Reported Benefits

Potent NF-κB Inhibition (In Vitro)

Consistently reduces NF-κB activation and pro-inflammatory cytokine production in LPS-stimulated macrophages, keratinocytes, and colonocytes. The anti-inflammatory potency in cell culture is well-documented across multiple independent laboratories.

In vitro data • Multiple labs • Consistent results

Colitis Improvement (Rodent)

Reduces disease severity in DSS and TNBS rodent colitis models when delivered by IP injection or nanoparticle-encapsulated oral formulation. Reduces colonic TNF-α, MPO, and histological damage. These are the most therapeutically promising preclinical findings.

Rodent colitis models • IP and nanoparticle oral routes • No human data

No Melanogenic or Appetite Effects

Unlike full-length α-MSH (which activates MC1R to increase melanin production and MC4R to suppress appetite), the KPV tripeptide does not produce tanning or appetite suppression. The anti-inflammatory activity is dissociated from these melanocortin effects, which is desirable for chronic anti-inflammatory use.

In vitro receptor binding data • Consistent with structural expectations

Favorable Safety Profile (Theoretical)

As a naturally-occurring endogenous tripeptide fragment, KPV is not expected to have significant toxicity. It is produced during normal α-MSH degradation. However, this theoretical safety has never been confirmed in human studies at the doses or routes used by the community.

Endogenous peptide fragment • Theoretical safety • No human safety data

Adverse Effects & Risks

Unknown Safety Profile in Humans

Zero human safety data exists. No adverse events have been documented because no human trials have been conducted. Rodent studies at IP doses showed no overt toxicity, but standard toxicology assessments have not been performed.

Complete absence of human data

Immunosuppression Concern

NF-κB is essential for innate and adaptive immune defense against infection. Chronic NF-κB suppression (if KPV achieves this systemically) could impair pathogen clearance. This is the same concern that applies to all anti-inflammatory biologics (anti-TNF, JAK inhibitors). The magnitude of KPV’s immunosuppressive potential at achievable systemic concentrations is unknown.

Mechanism-based theoretical risk

Near-Zero Oral Bioavailability

This is listed under side effects because it represents an economic and opportunity cost risk. Users taking oral KPV capsules (without nanoparticle encapsulation) are almost certainly not receiving any biologically active compound. The tripeptide is degraded by gastric acid and digestive enzymes. Money spent on oral KPV is likely wasted.

Tripeptide biochemistry + Dalmasso negative oral data

Extremely Short Half-Life (Expected)

Tripeptides in systemic circulation are rapidly degraded by serum peptidases (aminopeptidases, carboxypeptidases, DPP-4). KPV’s plasma half-life is expected to be on the order of minutes, not hours. Even SC injection may produce only transient systemic exposure. Continuous infusion or frequent dosing would theoretically be needed for sustained effect.

Peptide biochemistry • No PK data

Potential Pro-Tumorigenic Risk

NF-κB has tumor-suppressive functions in certain contexts (promoting apoptosis of damaged cells). Chronic NF-κB inhibition could theoretically promote survival of pre-malignant cells. This is a general class concern for NF-κB inhibitors, not KPV-specific, and remains theoretical.

Theoretical — NF-κB tumor biology literature

Evidence Base

Key studies

Preclinical — Colitis Model

PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation

Dalmasso G et al. • Gastroenterology • 2008 • Mouse DSS Colitis

Design & Findings

KPV reduced DSS colitis severity when administered IP (120 mcg/day) or as oral nanoparticle-encapsulated formulation (430 mcg/day). Free oral KPV was ineffective. KPV was taken up by colonocytes and immune cells via PepT1. Intracellular KPV inhibited NF-κB activation. Colonic TNF-α reduced by ~70%, MPO reduced by ~55%.

Significance

Published in the top-tier GI journal (Gastroenterology). Established the PepT1 uptake mechanism and nanoparticle delivery concept. The most translatable data for KPV in inflammatory bowel disease. The distinction between effective (nanoparticle/IP) and ineffective (free oral) routes is critically important.

Limitations

Mouse model only. DSS colitis is a chemical injury model that does not fully recapitulate human IBD pathophysiology. Nanoparticle formulation is a research tool, not a commercial product. No human GI data exists. The IP route is not practical for human use.

View on PubMed

In Vitro — Mechanism

α-MSH C-Terminal Tripeptide KPV Anti-Inflammatory Activity

Getting SJ et al. • J Leukoc Biol • 2006 • Cell Culture

Design & Findings

KPV (1–100 μM) inhibited NF-κB activation and reduced TNF-α, IL-6, and nitric oxide production in LPS-stimulated macrophages. The anti-inflammatory effect was partially retained in MC1R-null cells, suggesting both MC1R-dependent and MC1R-independent mechanisms. KPV was less potent than full-length α-MSH but still biologically active.

Significance

Establishes KPV’s intrinsic anti-inflammatory activity independent of the melanocortin receptor system. The MC1R-independent activity is important because it distinguishes KPV from simple MC1R agonists and suggests a unique intracellular mechanism.

Limitations

In vitro only. Micromolar concentrations may not be achievable systemically. Cell culture conditions do not replicate the complexity of in vivo inflammation. The relative contribution of MC1R-dependent vs. independent mechanisms is still debated.

View on PubMed

Preclinical — Skin Inflammation

α-MSH Peptides and Skin Inflammation

Brzoska T et al. • Endocr Rev • 2008 • Review + Original Data

Design & Findings

Comprehensive review of α-MSH and its fragments in skin immunology. KPV reduced UV-induced and cytokine-induced inflammatory responses in keratinocytes and fibroblasts. The skin’s endogenous melanocortin system produces α-MSH (and therefore KPV) as part of cutaneous immune homeostasis.

Significance

Places KPV in the context of the skin’s endogenous anti-inflammatory system. Provides rationale for topical KPV in inflammatory skin conditions. The endogenous production of the tripeptide in skin supports biological plausibility.

Limitations

Review article combining in vitro data. No human skin study with exogenous KPV. Topical delivery of a tripeptide across the stratum corneum is not addressed. The gap between endogenous production (local, picomolar) and exogenous therapeutic application (systemic or topical, micromolar) is enormous.

View on PubMed

Open Questions

Research gaps

Zero Human Clinical Trials

No registered or published human trial of KPV for any indication exists. The entire evidence base is cell culture and rodent models. Given the consistent preclinical anti-inflammatory data, a human IBD trial would be scientifically warranted — but none has been conducted.

Oral Bioavailability is Negligible

The most popular community route (oral capsule) is almost certainly ineffective. Free oral KPV was shown to be ineffective even in the rodent colitis model. Only nanoparticle-encapsulated oral KPV worked, and this formulation is not commercially available. Community users taking oral KPV capsules are very likely receiving no therapeutic benefit.

No Human PK Data

Plasma half-life, bioavailability, tissue distribution, and dose-response of KPV in humans are completely unknown. A tripeptide is expected to have a plasma half-life of minutes, raising fundamental questions about whether SC injection produces meaningful tissue exposure.

Nanoparticle Formulation Not Available

The colonic nanoparticle delivery system that worked in rodent colitis is a research formulation, not a product. Translating this to a human oral product requires pharmaceutical development (GMP manufacturing, stability testing, colonic release optimization) that has not been pursued.

No IBD Trial Despite Strong Rationale

The Gastroenterology paper from 2008 provided compelling preclinical IBD data. Nearly two decades later, no human IBD trial has been conducted. This gap likely reflects the challenge of developing a tripeptide therapeutic (short half-life, delivery challenges) and the lack of commercial sponsorship for a non-patentable fragment.

SC Route Pharmacologically Questionable

Even if SC injection achieves momentary systemic KPV levels, the expected minutes-long half-life means exposure is extremely transient. For chronic inflammatory conditions (IBD, dermatitis), transient daily exposure to an anti-inflammatory may be insufficient to produce sustained benefit. Sustained-release formulations or continuous delivery systems have not been explored.

Citations

References & further reading

1. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PubMed

2. Getting SJ, Christian HC, Lam CW, et al. Redundancy of a functional melanocortin 1 receptor in the anti-inflammatory actions of melanocortin peptides. J Leukoc Biol. 2006;80(2):374-382. PubMed

3. Brzoska T, Luger TA, Maaser C, et al. α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, anti-inflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602. PubMed

4. Luger TA, Brzoska T. α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. 2007;66(Suppl 3):iii52-iii55. PubMed

5. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. PubMed

All KPV on PubMed → ← Back to Research Library